A Canadian medical hashish firm has introduced the launch of a high-potency cannabidiol (CBD) oil for sufferers.
Napanee, Ontario-based VIVO Cannabis Inc. on Tuesday introduced the launch of the CBD+|O oil below its Beacon Medical model.
In accordance with VIVO CBD+|O oil is a 2:100 (THC:CBD) distillate-based hashish oil with 100mg CBD and fewer than 2mg delta-9 tetrahydrocannabinol (THC).
VIVO says that Beacon Medical formulates all of its hashish oil merchandise utilizing a non-GMO, food-grade medium-chain triglyceride (MCT) provider oil.
In accordance with VIVO, the provider oil ends in a ultimate product that’s scentless and flavorless.
VIVO CEO Ray Laflamme says that the corporate aspires to ship premium cannabinoid-based medical merchandise to sufferers by way of its dedication to the medical hashish market.
“We acknowledge that lots of our sufferers are searching for merchandise that meet their individualized wants,” says Laflamme. “And this newest addition to the Beacon Medical household of merchandise is a wonderful excessive efficiency CBD possibility for sufferers, and it will likely be obtainable to sufferers, docs, and hospitals alike.”
Laflamme says that the launch of Beacon Medical CBD+|O is in response to affected person insights that the corporate workforce has collected over time.
VIVO has additionally launched the Pediatric Compassionate Care Program to assist households and caregivers who require hashish to deal with varied medical situations.
In accordance with VIVO, eligible sufferers will obtain substantial reductions on all CBD merchandise from Beacon Medical, Canna Farms, Hearth, and Lumina.
VIVO says it stands robust on its patient-first strategy to ensure entry, alternative, and a constant provide for medical hashish sufferers in Canada, Australia, and Germany.
The brand new Beacon Medical CBD+|O high-potency oil is accessible by way of the Canna Farms e-commerce medical marketplace for sufferers in Canada.